218449-48-0

Basic information

• Product Name: tert-butyl 3-hydroxy-1-phenylpropylcarbamate
• Synonyms: tert-butyl 3-hydroxy-1-phenylpropylcarbamate;Carbamic acid, N-(3-hydroxy-1-phenylpropyl)-, 1,1-dimethylethyl este
• CAS NO: 218449-48-0
• Molecular Formula: C₁₄H₂₁NO₃
• Molecular Weight: 251.32144
• Mol File: 218449-48-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl 3-hydroxy-1-phenylpropylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 3-hydroxy-1-phenylpropylcarbamate(218449-48-0)
• EPA Substance Registry System: tert-butyl 3-hydroxy-1-phenylpropylcarbamate(218449-48-0)

Safety Data

• Hazardous Substances Data: 218449-48-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl 3-hydroxy-1-phenylpropylcarbamate is used as an anxiolytic and sedative medication for the treatment of anxiety, tension, and muscle spasm disorders. Its mechanism of action involves the enhancement of GABA activity in the brain, which contributes to its calming and relaxing effects.
However, due to its high potential for abuse and the risks of dependence and addiction, the use of meprobamate has declined in recent years. Despite these concerns, it remains an important compound in the pharmaceutical industry for specific applications where its anxiolytic and sedative properties are required.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 14593-04-5 3-amino-3-phenyl-1-propanol 
• 3646-50-2 3-Amino-3-phenylpropionic acid 
• 100-52-7 benzaldehyde 
• 4393-21-9 1-(phenyl)allylamine 
• 91230-12-5 (1-phenyl-allyl)-carbamic acid tert-butyl ester 

Downstream Products

• 374725-03-8 tert-butyl (-formyl-1-phenylethyl)carbamate 
• 1620488-63-2 N-(3-azido-1-phenylpropyl)-2-hydroxyiminoacetamide 
• 1630028-91-9 C₆H₁₁NO₅*C₉H₁₂N₄ 
• 1620488-61-0 3-azido-1-phenylpropylamine 
• 1620488-58-5 tert-butyl (3-azido-1-phenylpropyl)carbamate 
• 1620488-67-6 C₁₅H₂₁N₅O₄ 
• 432042-06-3 C₁₀H₁₅NO 

Relevant articles and documents

Base-induced Sommelet–Hauser rearrangement of N-(α-(2-oxyethyl)branched)benzylic glycine ester-derived ammonium salts via a chelated intermediate

The base-induced Sommelet–Hauser (S–H) rearrangement of N-(α-branched)benzylic glycine ester-derived ammonium salts 1 was investigated. When the α-branched substituent was a simple alkyl, such as a methyl or butyl, desired S–H rearrangement product 2 was obtained in low yield with formation of the [1,2] Stevens rearranged 4 and Hofmann eliminated products 5 and 6. However, when the α-branched substituent had a 2-oxy moiety, such as 2-acetoxyethyl or 2-benzoyloxyethyl, the yields of 2 were improved. These results could be explained by formation of chelated intermediate C that stabilizes the carbanionic ylide, and the subsequent initial dearomative [2,3] sigmatropic rearrangement would be accelerated. The existence of C was supported by mechanistic experiments. This enhancement effect is not very strong or effective; however, it will expand the synthetic usefulness of ammonium ylide rearrangements.

Compound with cyclophosphamide structure and preparation method thereof

The invention discloses a compound with a cyclophosphamide structure. The compound can be used for treating mammal hepatitis c infection. The invention also discloses a preparation method of the compound. Diphenyl phosphite is used as a raw material so th

Enzyme-catalyzed cascade synthesis of hydroxyiminoacetamides

In order to synthesize N-(3-azido-1-phenylpropyl)-2-hydroxyiminoacetamide, a key compound for the preparation of acetylcholinesterase (AChE) reactivators of the N-substituted 2-hydroxyiminoacetamide type, it was necessary to develop a method for forming a

ALPHA2B AND ALPHA2C AGONISTS

Described herein are compounds that can be useful as bioactive agents. More specifically, the compounds described herein can be useful as both α2B and α2C adrenergic agonists. Methods of synthesis and administration of the compounds are also disclosed.

Structure-activity relationships of 1,3,5-triazine-2,4,6-triones as human gonadotropin-releasing hormone receptor antagonists

SAR studies of 1,3,5-triazine-2,4,6-triones as human gonadotropin-releasing hormone receptor antagonists resulted in potent compounds. The best compound from the series had a binding affinity of 2 nM.

Oxazolidinones as alpha 1A receptor antagonists

This invention is directed to oxazolidinone compounds which are selective antagonists for human alpha 1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the alpha 1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.